Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Next Previous
X
Search
Trial Profile

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketorolac/phenylephrine (Primary) ; Anti-inflammatories; Mydriatics
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 22 May 2015 According to a media release from the European Medicines Agency, Omidria [ketorolac/phenylephrine] has received a positive opinion for from the Committee for Medicinal Products for Human Use (CHMP) for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.
    • 19 Apr 2013 The phase II and III data analyses will be included in both the US and European marketing applications for OMS 302, according to an Omeros media release.
    • 19 Apr 2013 Additional data from analyses of phase II and III trials will be presented at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress, according to an Omeros media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top